The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Thalia.de
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, DE. (EUR 0.00) Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Thalia.de
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, DE. (EUR 0.00) Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer 30.03.2006, Springer, Springer<
Orellfuessli.ch
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, zzgl. Versandkosten. (EUR 16.85) Details...
(*) Derzeit vergriffen bedeutet, dass dieser Titel momentan auf keiner der angeschlossenen Plattform verfügbar ist.
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, DE. (EUR 0.00)
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer PDF, Springer, 30.03.2006, Springer, 2006<
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, DE. (EUR 0.00)
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkab… Mehr…
The aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles. TOC:From the Contents.- Protein Kinase Inhibitors for the Treatment of Disease; the Promise and the Problems.- Part 1: General Aspects of PKs Inhibition.- New Design Strategies for Ligands that Target Protein Kinase Mediated Protein-Protein Interactions.- Part 2: Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones, a Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase -3. Pharmacological Potential of p38 MAPK Inhibitors. Inhibitors of PKA and Related Protein Kinases. Inhibitors of Protein Kinase CK2: Structural Aspects. Aminoglycoside Kinases and Antibiotic Resistance.- Part 3: Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets. Structure-Based Design of PTP Inhibitors. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target. Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Part 4: Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression Using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. Targeted Therapy with Imatinib: An Exception or a Rule? Clinical Aspects of Imantinib Therapy. Isoquinolinesulfonamide, a Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy. Discovery and Development of Iressa - The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. eBook Springer 30.03.2006, Springer, Springer<
Nr. 24485740. Versandkosten:, Sofort per Download lieferbar, zzgl. Versandkosten. (EUR 16.85)
1Da einige Plattformen keine Versandkonditionen übermitteln und diese vom Lieferland, dem Einkaufspreis, dem Gewicht und der Größe des Artikels, einer möglichen Mitgliedschaft der Plattform, einer direkten Lieferung durch die Plattform oder über einen Drittanbieter (Marketplace), etc. abhängig sein können, ist es möglich, dass die von eurobuch angegebenen Versandkosten nicht mit denen der anbietenden Plattform übereinstimmen.
Detailangaben zum Buch - Inhibitors of Protein Kinases and Protein Phosphates
EAN (ISBN-13): 9783540266709 ISBN (ISBN-10): 3540266704 Erscheinungsjahr: 2006 Herausgeber: Springer Berlin 458 Seiten Sprache: eng/Englisch
Buch in der Datenbank seit 2009-12-22T06:28:52+01:00 (Zurich) Detailseite zuletzt geändert am 2023-02-11T12:18:16+01:00 (Zurich) ISBN/EAN: 9783540266709
ISBN - alternative Schreibweisen: 3-540-26670-4, 978-3-540-26670-9 Alternative Schreibweisen und verwandte Suchbegriffe: Autor des Buches: born, pinna, lorenzo, cohen Titel des Buches: inhibitors protein, kina kina, handbook experimental pharmacology
Daten vom Verlag:
Autor/in: Lorenzo A. Pinna; Patricia T.W. Cohen Titel: Handbook of Experimental Pharmacology; Inhibitors of Protein Kinases and Protein Phosphates Verlag: Springer; Springer Berlin 458 Seiten Erscheinungsjahr: 2006-03-30 Berlin; Heidelberg; DE Gedruckt / Hergestellt in Deutschland. Sprache: Englisch 523,23 € (DE) 537,90 € (AT) 590,00 CHF (CH) Available X, 458 p.
EA; E107; eBook; Nonbooks, PBS / Medizin/Pharmazie; Pharmakologie; Verstehen; Anticancer drugs; Antidiabetes targets; Calcineurin-Inhibitor; Cell signalling; Glycogen; Immunosuppressants; Signal transduction therapy; B; Pharmacology/Toxicology; Oncology; Pathology; Medical Biochemistry; Pharmacology; Oncology; Pathology; Medical Biochemistry; Biomedical and Life Sciences; Onkologie; Pathologie; Medizinische Chemie, Pharmazeutische Chemie; BB
Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems.- General Aspects of PKs Inhibition.- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3.- Pharmacological Potential of p38 MAPK Inhibitors.- Inhibitors of PKA and Related Protein Kinases.- Inhibitors of Protein Kinase CK2: Structural Aspects.- Aminoglycoside Kinases and Antibiotic Resistance.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets.- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors.- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target.- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus.- Targeted Therapy with Imatinib: An Exception or a Rule?.- Clinical Aspects of Imatinib Therapy.- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy.- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
Weitere, andere Bücher, die diesem Buch sehr ähnlich sein könnten:
